Lacey Rachel, Evans Alex
Department of Gastroenterology, Royal Berkshire NHS Trust, Reading, UK.
BMJ Case Rep. 2014 Dec 24;2014:bcr2014205764. doi: 10.1136/bcr-2014-205764.
A 48-year old woman with metastatic breast cancer and extensive bone marrow infiltration was admitted with extreme lethargy, jaundice and deranged liver function tests. She had been started on anastrozole in May 2013 for bony metastases, detected on a bone scan. A CT scan performed at that time had shown no evidence of metastatic or nodal disease elsewhere. Over the subsequent 2 months, the patient had become progressively jaundiced. Outpatient abdominal ultrasound and CT liver had shown a fatty liver with no focal lesions. She was admitted in August 2013 with bilirubin 567, alkaline phosphatase 385, alanine aminotransferase 98, albumin 25 and international normalised ratio 1.9. The patient ultimately had a liver biopsy, which demonstrated features of drug-induced steatohepatitis, and anastrozole was found to have been the probable cause. This case explores the differentials of jaundice in a patient with cancer and describes a rare cause of drug-induced liver injury.
一名48岁患有转移性乳腺癌且骨髓广泛浸润的女性因极度嗜睡、黄疸及肝功能检查异常而入院。她于2013年5月开始使用阿那曲唑治疗骨转移,骨扫描发现了骨转移。当时进行的CT扫描未显示其他部位有转移或淋巴结病变。在随后的2个月里,患者黄疸逐渐加重。门诊腹部超声和肝脏CT显示为脂肪肝,无局灶性病变。她于2013年8月入院,胆红素567、碱性磷酸酶385、谷丙转氨酶98、白蛋白25及国际标准化比值1.9。患者最终进行了肝活检,结果显示为药物性脂肪性肝炎,阿那曲唑被认为是可能的病因。本病例探讨了癌症患者黄疸的鉴别诊断,并描述了一种罕见的药物性肝损伤病因。